Structure-based design of subtype-selective psychedelic analogs.
Abstract
Classical psychedelics exert hallucinogenic and therapeutic effects primarily through activation of serotonin 2 A receptor (5-HT<sub>2A</sub>R), offering promise as transformative treatments for neuropsychiatric disorders. However, their concurrent activation of 5-HT<sub>2B</sub>R-associated with cardiac valvulopathy-raises serious safety concerns, underscoring the need for subtype-selective psychedelics. To address this, we determine the cryo-EM structure of 5-HT<sub>2A</sub>R and perform a comparative structural analysis of the orthosteric binding pockets (OBPs) of 5-HT<sub>2A</sub>R and 5-HT<sub>2B</sub>R. Guided by key residue differences, we develop a trigonal pharmacophore model to inform the design of 5-HT<sub>2A</sub>R-selective agonists that avoid 5-HT<sub>2B</sub>R activation. Using this model, we design and synthesize two compound series that selectively activate 5-HT<sub>2A</sub>R while antagonizing 5-HT<sub>2B</sub>R. Molecular basis of subtype selectivity is confirmed by five additional cryo-EM structures of receptor-ligand complexes. Selected compounds also exhibit antidepressant-like efficacy in animal models. Our findings provide a strategy for the development of safer, subtype-selective psychedelic analogs with therapeutic potential.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.